But Novo Nordisk, the Danish pharma big behind the ‘miracle’ drug, has already admitted that only a ‘proportion’ of already restricted inventory will be shared with the health service, with the rest allocated to personal firms. Experts hit out at …
But Novo Nordisk, the Danish pharma big behind the ‘miracle’ drug, has already admitted that only a ‘proportion’ of already restricted inventory will be shared with the health service, with the rest allocated to personal firms. Experts hit out at …